by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
With the ultimate goal of having a cure for multiple myeloma, researchers and clinicians hope to assemble strategies that will incorporate new and ......READ MORE
by Kenneth C. Anderson, MD; Sagar Lonial, MD, FACP; and S. Vincent Rajkumar, MD
Chimeric antigen receptor (CAR) T-cell therapy can achieve very high response rates in heavily pretreated multiple myeloma, allowing many patients ......READ MORE
The management of multiple myeloma is evolving with the emergence of new agents and new approaches to treatment. The paradigm is shifting in severa......READ MORE
High-risk and ultra-high-risk multiple myeloma, characterized by the presence of cytogenetic abnormalities and/or extramedullary disease, represent......READ MORE
Since the manufacturing of chimeric antigen receptor (CAR) T-cell therapy takes time, bridging therapy is often delivered to ensure that the diseas......READ MORE
The use of chimeric antigen receptor (CAR) T-cell therapy can achieve remarkable responses in heavily pretreated patients with multiple myeloma. Cy......READ MORE
